(Q42792700)

7 November 2017

Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. (English)

1 reference

7 November 2017

1 reference

Antonio da Silva

1

1 reference

7 November 2017

Ulrich Kronthaler

2

1 reference

7 November 2017

Vera Koppenburg

3

1 reference

7 November 2017

Martin Fink

4

1 reference

7 November 2017

Ines Meyer

5

1 reference

7 November 2017

Anastassia Papandrikopoulou

6

1 reference

7 November 2017

Matthias Hofmann

7

1 reference

7 November 2017

Thomas Stangler

8

1 reference

7 November 2017

Jan Visser

9

1 reference

7 November 2017

24 January 2014

1 reference

7 November 2017

1 reference

7 November 2017

55

1 reference

7 November 2017

7

1 reference

7 November 2017

1609-1617

1 reference

Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

27 May 2018

Rituximab biosimilars

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

The economic pressures for biosimilar drug use in cancer medicine

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Worldwide experience with biosimilar development

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Clinical pharmacokinetics of therapeutic monoclonal antibodies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Rituximab: mechanism of action

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Engineered therapeutic antibodies with improved effector functions

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Trends in US approvals: new biopharmaceuticals and vaccines.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Rituximab: mechanism of action and resistance

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133973

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

16 August 2018

1 reference

12 December 2020

Advances in the assessment and control of the effector functions of therapeutic antibodies

1 reference

12 December 2020

Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences

1 reference

12 December 2020

The state of the art in the development of biosimilars

1 reference

12 December 2020

10.3109/10428194.2013.843090

Identifiers

DOI

1 reference

release_dqp4apvawff5pdtlmhauzskapq

7 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dqp4apvawff5pdtlmhauzskapq

24 November 2022

mapped directly with Wikidata item

1 reference

7 November 2017

PubMed publication ID

24024472

1 reference